Novo Nordisk has integrated OpenAI's artificial intelligence across its operations to accelerate the development of new obesity medications. The partnership leverages AI to streamline research and development processes.
Novo Nordisk A/S, the Danish pharmaceutical giant behind blockbuster obesity drugs like Ozempic and Wegovy, is tapping OpenAI's technology to speed up drug discovery and development.
The integration of OpenAI's AI tools across the company marks a significant step in pharma's broader adoption of generative AI. Novo Nordisk joins a growing list of healthcare companies exploring how large language models and machine learning can compress timelines in the notoriously lengthy drug development process.
Drug development traditionally takes 10-15 years and costs billions to bring a single medication to market. AI applications can accelerate various stages, from initial compound screening to analyzing clinical trial data and identifying patient populations for trials.
For Novo Nordisk, the timing is strategic. The company dominates the exploding obesity drug market, with demand for GLP-1 receptor agonists vastly outpacing supply. Accelerating development of next-generation treatments could extend its market advantage as competitors rush to develop competing medications.
OpenAI's partnership with a major pharmaceutical player underscores the enterprise adoption trajectory of its technology beyond software development and creative industries. Pharma companies have invested heavily in AI initiatives, and partnerships with leading AI providers are becoming more common.
The scope of Novo Nordisk's integration with OpenAI's technology across the company suggests deployment beyond a single department. This could encompass research operations, regulatory documentation, data analysis, and other administrative functions.
Details on the financial terms of the partnership were not disclosed. The announcement comes as regulatory scrutiny of AI in healthcare continues to evolve, particularly regarding validation, transparency, and liability in clinical decision-making contexts.
Novo Nordisk faces intense pressure to meet global demand for obesity treatments as the market expands and competitors develop alternatives. Accelerating drug pipelines through AI integration addresses both competitive and supply-side challenges in the rapidly growing sector.
India's JioStar is integrating generative AI into its streaming platform to enable conversational recommendations for shopping and entertainment. The move positions AI-powered interactions as a core revenue and engagement driver.
Cognition has released SWE-1.7, a new AI model trained using Kimi K2.7 that processes text at 1,000 tokens per second. The company claims the model matches performance of GPT-5.5 and Claude Opus 4.8 while reducing costs.
Westpac Banking Corp. is ramping up oversight of artificial intelligence costs by tracking token usage across the organization and directing routine tasks to cheaper models.
Google's Gemini app can now generate lifelike videos featuring AI avatars of users. The technology creates digital clones that mimic appearance and behavior with striking accuracy.